Zhitong Finance App News, Kexing Pharmaceutical (688136.SH) issued an announcement. Recently, Shenzhen Kexing Pharmaceutical Co., Ltd. (“Shenzhen Kexing” for short), a wholly-owned subsidiary of the company, received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and the State Drug Administration approved the TL1A monoclonal antibody innovative drug “GB20 injection” independently developed by Shenzhen Kexing to conduct clinical trials.

GB20 injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It can specifically bind TL1A to block the cascade of intestinal inflammation and reduce intestinal mucosal inflammatory damage. It is intended for the treatment of inflammatory bowel diseases (including ulcerative colitis and Crohn's disease). Preclinical studies have shown that the molecules of GB20 injection have good activity in vivo and in vitro, and can effectively relieve IBD symptoms and improve intestinal function and microstructure in animal models. The anti-inflammatory and anti-fibrotic efficacy is superior to that of competitive products. GB20 injection has been modified for a long time, has good PK/PD characteristics, and has the potential to develop high-concentration formulations. It is expected to reduce the frequency of clinical administration and improve patient compliance.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.